Findings

What do systematic reviews say?

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

CVnCoV – CureVac AG vs placebo

Serious adverse eventsk

CVnCoV – CureVac AG showed no clear difference in serious adverse eventsk compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.24 [0.9, 1.71]
1 study · 39529 participants
Low

CVnCoV – CureVac AG vs placebo

Local reactogenicity events

CVnCoV – CureVac AG leads to higher local reactogenicity eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 3.51 [3.24, 3.81]
1 study · 3982 participants
High

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 43390 participants
Moderate

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 43390 participants
High

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

All‐cause mortalityf

ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.48 [0.2, 1.14]
5 studies · 56727 participants
Low

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Systemic reactogenicity events

ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher systemic reactogenicity eventsi compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 3.93 [2.11, 7.29]
1 study · 256 participants
Moderate

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46077 participants
High

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Any adverse eventl

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 57580 participants
Low

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Serious adverse eventso

ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in serious adverse eventso compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.88 [0.72, 1.07]
7 studies · 58182 participants
Moderate

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

Local reactogenicity events

ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher local reactogenicity eventsi compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 6.44 [2.98, 13.92]
1 study · 256 participants
Moderate

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

All‐cause mortalityg

BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in all‐cause mortalityg compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.07 [0.52, 2.22]
1 study · 43847 participants
Low

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39058 participants
High

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39058 participants
High

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

All‐cause mortalityb

AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.25 [0.09, 0.67]
1 study · 43783 participants
High

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Serious adverse eventsb

AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.22]
1 study · 43783 participants
Moderate

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Systemic reactogenicity events

AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.83 [1.29, 2.6]
2 studies · 7222 participants
High

AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo

Any adverse eventh

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 7222 participants
Low

Gam‐COVID‐VAC – Sputnik V vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found